Navi Mumbai-based Inventurus Knowledge Solutions, often referred to as IKS Health, is a provider of technology-driven healthcare solutions established in 2006. The company runs a care enablement platform designed to assist US-based healthcare organizations with operational, clinical, and administrative functions.
IKS Health boasts a market capitalization of approximately ₹24,552.12 crore, with its shares falling nearly 3% over the previous year.
Watch the full discussion here
“We believe there’s an opportunity worth about half a billion dollars in the remaining 500 hospitals to implement our system of action,” Gupta explained, highlighting the principal growth driver from this acquisition.
This acquisition grants IKS access to TrueBridge’s network of around 700 US hospitals, with approximately 200 currently utilizing its revenue cycle system. Gupta emphasized the company’s plan to integrate its platform and cross-sell solutions to those remaining hospitals to unlock growth.
“The primary avenue for growth will involve cross-selling the RCM system of action to their electronic health record (EHR) user base,” he noted, adding that integrating IKS’ execution model will be essential for revenue scaling.
Also Read:
Dr Reddys gains may be short-lived; Cipla, Sun Pharma face risks: Vishal Manchanda
Although growth prospects appear strong, margins are anticipated to decrease initially before rebounding. “Margins are projected to drop to approximately 26% pro forma upon closing this deal,” Gupta stated, but assured that the company has a history of reclaiming profitability.
He anticipates a recovery in the medium term. “We are confident about returning our margins to the early to mid-30s,” Gupta stated, with a timeline of “18 to 24 months” for such a transition.
Despite the anticipated short-term margin effects, the transaction is expected to enhance earnings from the outset. “From the closing date, the deal is EPS accretive,” he said, considering interest expenses and amortization.
IKS is primarily financing the acquisition through debt, which will heighten leverage in the short term. “We are assuming $557 million in additional debt… overall, it will amount to about $600 million in gross debt,” Gupta mentioned.
Nevertheless, he outlined a clear plan for deleveraging alongside growth objectives. “We’ve set ourselves a target of ₹3000 crore in EBITDA and reducing net debt to ₹300 crore by 2029-30 (FY30),” he noted, reflecting strong confidence in cash flow generation.
Regarding currency risk, Gupta indicated that the company’s dollar-linked revenues serve as a natural hedge. “Our revenues are in dollars… the depreciation of the rupee benefits us on the margin front as well,” he pointed out.
Catch all the latest updates from the stock market here
